Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program.
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS.
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid